Adenovirus-mediated gene transfer in dog prostate: A preclinical study of a relevant model system for gene therapy of human prostatic cancer

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 1, 1999, Pages 25-35

  Andrawiss, M ^a,f   Opolon, P ^a   Benihoud, K ^a   Devauchelle, P ^c   Di Falco, N ^a   Villette, J M ^b   Kremer, E ^a,e   Saulnier, P ^d   Berthon, P ^b   Perricaudet, M ^a   Cussenot, O ^b  

^a CNRS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Alfort Veterinary School   (France)

^d IGR   (France)

^e GÉNÉTHON   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adenovirus; Gene therapy; Prostate cancer

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CANCER REGRESSION; CELL CULTURE; DOG; EPITHELIUM CELL; GENE THERAPY; GENE TRANSFER; IMMUNE RESPONSE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; VIRUS GENOME;

EID: 0033049362     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500278     Document Type: Article

References (42)

1. Carducci MA, Ayyagari SR, Sanda MG, Simons JW. Gene therapy for human prostate cancer. Cancer Supp 1995; 75: 2013-2020.
2. Horwitz MZ. Adenoviruses. In: Fields BN, Knipe DM, Howley PM (supp.) (eds). Fields Virology. Lippincott-Raven Publishers: Philadelphia, 1996, pp 2141-2171.
3. Kremer EJ, Perricaudet M. Adenovirus and adeno-associated virus mediated gene transfer. Br Med Bull 1995; 51: 1-14.
4. Vieweg J et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54: 1760-1765.
5. Vieweg J et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995; 55: 2366-2372.
6. Moody DB et al. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 1994; 24: 244-251.
7. Eastham JA et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55: 5151-5155.
8. Eastham JA et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996; 7: 515-523.
9. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55: 4210-4213.
10. Cheng L et al. CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy. J Natl Cancer Inst 1996; 88: 607-611.
11. Waters DJ, Bostwick DG. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res 1997; 17: 000-000.
12. Smith JG et al. Intracranial administration of adenovirus expressing HSV-tk in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. Hum Gene Ther 1997; 8: 943-954.
13. Stratford-Perricaudet L, Perricaudet M. Widespread long-term gene transfer of mouse skeletal muscles and heart. J Clin Invest 1992; 90: 626-630.
14. Graham FL, van der Eb EJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
15. Graham FL, Smiley J, Russel WC, Nairu R. Characteristics of a human cell line transformed by the DNA from human adenovirus 5. J Gene Virol 1977; 36: 59-72.
16. Stratford-Perricaudet LD et al. Evaluation of the transfer and expression in mice of an enzyme encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241-256.
17. Rogers MF et al. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. New Engl J Med 1989; 320: 1649-1654.
18. Khan G, Kangro HO, Coates PJ, Heath RB. Inhibitory effects of urine on the polymerase chain reaction for cytomegalovirus DNA. J Clin Pathol 1991; 4: 360-365.
19. Tursz T et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996; 88: 1857-1863.
20. Thimmappaya B, Weinberger C, Schneider RJ, Shenk T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 1982; 31: 543-551.
21. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467-3473.
22. Wernert N, Seitz G. Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma. Path Res Pract 1987; 182: 617-626.
23. Cussenot O et al. Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue section. Exp Cell Res 1994; 214: 83-92.
24. Berthon P et al. Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells: Differentiation pattern of non-tumorigenic cell lines. Int J Oncol 1995; 6: 333-343.
25. McNeal JE, Gleason DF. Classification de Gleason des adénocarcinomes prostatiques. Ann Pathol 1991; 11: 163-168.
26. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
27. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2A. Hum Gene Ther 1994; 5: 1217-1229.
28. McCoy RD et al. Pulmonary inflammation induced by incomplete or inactivatedadenoviralparticles. Hum Gene Ther 1995; 6: 1553-1560.
29. Bohle W et al. Postoperative active specific immunization colorectal cancer patient with virus-modified autologous tumor-cell vaccine. Cancer 1990; 66: 1517-1523.
30. Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical Management of stage II malignant melanoma with Newcastle Disease Virus Oncolysate. Cancer 1983; 52: 856-860.
31. Plaksin D et al. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle Disease Virus (NDV). Int J Cancer 1994; 59: 796-801.
32. Abina MA et al. LacZ gene transfer into tumor cells abrogates tumorogenicity and protects mice against the development of further tumors. Gene Ther 1996; 3: 212-216.
33. Tripathy SK, Black HB, Goldwasser E, Leiden JM . Immune response to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med 1996; 2: 545-550.
34. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acnd Sci USA 1994; 91: 4407-4411.
35. Yang Y et al. Inactivation of E2A in recombinant adenoviruses improves the prospect for gene therapy for cystic fibrosis. Nature Genet 1994; 7: 362-369.
36. Yang Y, Li Q, Ertl HCJ, Wilson J. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
37. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune response to adenovirus vector-transduced cells in mouse lungs. J Virol 1996; 70: 7209-7212.
38. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in viva. Gene Ther 1996; 3: 137-144.
39. Gao G-P, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943.
40. Dedieu J-F et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997; 71: 4626-4637.
41. Huard J et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2: 107-115.
42. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-3593.